Jonathon R Campbell1, Aashna Uppal1, Olivia Oxlade1, Federica Fregonese1, Mayara Lisboa Bastos1, Zhiyi Lan1, Stephanie Law1, Chi Eun Oh1, W Alton Russell1, Giorgia Sulis1, Nicholas Winters1, Mercedes Yanes-Lane1, Marc Brisson1, Sonia Laszlo1, Timothy G Evans1, Dick Menzies2. 1. Research Institute of the McGill University Health Centre (Campbell, Oxlade, Fregonese, Menzies, Oh, Bastos, Sulis); Faculty of Medicine (Campbell, Menzies, Winters, Sulis, Uppal, Yanes-Lane, Lan), McGill University; McGill International TB Centre (Campbell, Oxlade, Fregonese, Menzies, Bastos, Sulis, Law); Department of Economics (Laszlo) and School of Population and Global Health (Evans), McGill University, Montréal, Que.; Department of Management Science and Engineering (Russell), Stanford University, Stanford, Calif.; Department of Pediatrics (Oh), Kosin University College of Medicine, Busan, Republic of Korea; Department of Epidemiology (Bastos), Social Medicine Institute, State University of Rio de Janeiro, Rio de Janeiro, Brazil; Department of Global Health and Social Medicine (Law), Harvard Medical School, Boston, Mass.; Département de médicine social et preventive (Brisson), Université Laval, Québec, Que. 2. Research Institute of the McGill University Health Centre (Campbell, Oxlade, Fregonese, Menzies, Oh, Bastos, Sulis); Faculty of Medicine (Campbell, Menzies, Winters, Sulis, Uppal, Yanes-Lane, Lan), McGill University; McGill International TB Centre (Campbell, Oxlade, Fregonese, Menzies, Bastos, Sulis, Law); Department of Economics (Laszlo) and School of Population and Global Health (Evans), McGill University, Montréal, Que.; Department of Management Science and Engineering (Russell), Stanford University, Stanford, Calif.; Department of Pediatrics (Oh), Kosin University College of Medicine, Busan, Republic of Korea; Department of Epidemiology (Bastos), Social Medicine Institute, State University of Rio de Janeiro, Rio de Janeiro, Brazil; Department of Global Health and Social Medicine (Law), Harvard Medical School, Boston, Mass.; Département de médicine social et preventive (Brisson), Université Laval, Québec, Que. dick.menzies@mcgill.ca.
Abstract
BACKGROUND: Testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is largely passive, which impedes epidemic control. We defined active testing strategies for SARS-CoV-2 using reverse transcription polymerase chain reaction (RT-PCR) for groups at increased risk of acquiring SARS-CoV-2 in all Canadian provinces. METHODS: We identified 5 groups who should be prioritized for active RT-PCR testing: contacts of people who are positive for SARS-CoV-2, and 4 at-risk populations - hospital employees, community health care workers and people in long-term care facilities, essential business employees, and schoolchildren and staff. We estimated costs, human resources and laboratory capacity required to test people in each group or to perform surveillance testing in random samples. RESULTS: During July 8-17, 2020, across all provinces in Canada, an average of 41 751 RT-PCR tests were performed daily; we estimated this required 5122 personnel and cost $2.4 million per day ($67.8 million per month). Systematic contact tracing and testing would increase personnel needs 1.2-fold and monthly costs to $78.9 million. Conducted over a month, testing all hospital employees would require 1823 additional personnel, costing $29.0 million; testing all community health care workers and persons in long-term care facilities would require 11 074 additional personnel and cost $124.8 million; and testing all essential employees would cost $321.7 million, requiring 25 965 added personnel. Testing the larger population within schools over 6 weeks would require 46 368 added personnel and cost $816.0 million. Interventions addressing inefficiencies, including saliva-based sampling and pooling samples, could reduce costs by 40% and personnel by 20%. Surveillance testing in population samples other than contacts would cost 5% of the cost of a universal approach to testing at-risk populations. INTERPRETATION: Active testing of groups at increased risk of acquiring SARS-CoV-2 appears feasible and would support the safe reopening of the economy and schools more broadly. This strategy also appears affordable compared with the $169.2 billion committed by the federal government as a response to the pandemic as of June 2020.
BACKGROUND: Testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is largely passive, which impedes epidemic control. We defined active testing strategies for SARS-CoV-2 using reverse transcription polymerase chain reaction (RT-PCR) for groups at increased risk of acquiring SARS-CoV-2 in all Canadian provinces. METHODS: We identified 5 groups who should be prioritized for active RT-PCR testing: contacts of people who are positive for SARS-CoV-2, and 4 at-risk populations - hospital employees, community health care workers and people in long-term care facilities, essential business employees, and schoolchildren and staff. We estimated costs, human resources and laboratory capacity required to test people in each group or to perform surveillance testing in random samples. RESULTS: During July 8-17, 2020, across all provinces in Canada, an average of 41 751 RT-PCR tests were performed daily; we estimated this required 5122 personnel and cost $2.4 million per day ($67.8 million per month). Systematic contact tracing and testing would increase personnel needs 1.2-fold and monthly costs to $78.9 million. Conducted over a month, testing all hospital employees would require 1823 additional personnel, costing $29.0 million; testing all community health care workers and persons in long-term care facilities would require 11 074 additional personnel and cost $124.8 million; and testing all essential employees would cost $321.7 million, requiring 25 965 added personnel. Testing the larger population within schools over 6 weeks would require 46 368 added personnel and cost $816.0 million. Interventions addressing inefficiencies, including saliva-based sampling and pooling samples, could reduce costs by 40% and personnel by 20%. Surveillance testing in population samples other than contacts would cost 5% of the cost of a universal approach to testing at-risk populations. INTERPRETATION: Active testing of groups at increased risk of acquiring SARS-CoV-2 appears feasible and would support the safe reopening of the economy and schools more broadly. This strategy also appears affordable compared with the $169.2 billion committed by the federal government as a response to the pandemic as of June 2020.
Authors: Melissa M Arons; Kelly M Hatfield; Sujan C Reddy; Anne Kimball; Allison James; Jesica R Jacobs; Joanne Taylor; Kevin Spicer; Ana C Bardossy; Lisa P Oakley; Sukarma Tanwar; Jonathan W Dyal; Josh Harney; Zeshan Chisty; Jeneita M Bell; Mark Methner; Prabasaj Paul; Christina M Carlson; Heather P McLaughlin; Natalie Thornburg; Suxiang Tong; Azaibi Tamin; Ying Tao; Anna Uehara; Jennifer Harcourt; Shauna Clark; Claire Brostrom-Smith; Libby C Page; Meagan Kay; James Lewis; Patty Montgomery; Nimalie D Stone; Thomas A Clark; Margaret A Honein; Jeffrey S Duchin; John A Jernigan Journal: N Engl J Med Date: 2020-04-24 Impact factor: 91.245
Authors: Sheikh Taslim Ali; Lin Wang; Eric H Y Lau; Xiao-Ke Xu; Zhanwei Du; Ye Wu; Gabriel M Leung; Benjamin J Cowling Journal: Science Date: 2020-07-21 Impact factor: 47.728
Authors: Joel Hellewell; Sam Abbott; Amy Gimma; Nikos I Bosse; Christopher I Jarvis; Timothy W Russell; James D Munday; Adam J Kucharski; W John Edmunds; Sebastian Funk; Rosalind M Eggo Journal: Lancet Glob Health Date: 2020-02-28 Impact factor: 26.763
Authors: Ioanna Smyrlaki; Martin Ekman; Antonio Lentini; Nuno Rufino de Sousa; Natali Papanicolaou; Martin Vondracek; Johan Aarum; Hamzah Safari; Shaman Muradrasoli; Antonio Gigliotti Rothfuchs; Jan Albert; Björn Högberg; Björn Reinius Journal: Nat Commun Date: 2020-09-23 Impact factor: 14.919
Authors: Suzie Kratzer; Lisa M Pfadenhauer; Renke L Biallas; Robin Featherstone; Carmen Klinger; Ani Movsisyan; Julia E Rabe; Julia Stadelmaier; Eva Rehfuess; Katharina Wabnitz; Ben Verboom Journal: Cochrane Database Syst Rev Date: 2022-06-06
Authors: Shari Krishnaratne; Hannah Littlecott; Kerstin Sell; Jacob Burns; Julia E Rabe; Jan M Stratil; Tim Litwin; Clemens Kreutz; Michaela Coenen; Karin Geffert; Anna Helen Boger; Ani Movsisyan; Suzie Kratzer; Carmen Klinger; Katharina Wabnitz; Brigitte Strahwald; Ben Verboom; Eva Rehfuess; Renke L Biallas; Caroline Jung-Sievers; Stephan Voss; Lisa M Pfadenhauer Journal: Cochrane Database Syst Rev Date: 2022-01-17
Authors: Guillaume Butler-Laporte; Alexander Lawandi; Ian Schiller; Mandy Yao; Nandini Dendukuri; Emily G McDonald; Todd C Lee Journal: JAMA Intern Med Date: 2021-03-01 Impact factor: 21.873
Authors: Shari Krishnaratne; Lisa M Pfadenhauer; Michaela Coenen; Karin Geffert; Caroline Jung-Sievers; Carmen Klinger; Suzie Kratzer; Hannah Littlecott; Ani Movsisyan; Julia E Rabe; Eva Rehfuess; Kerstin Sell; Brigitte Strahwald; Jan M Stratil; Stephan Voss; Katharina Wabnitz; Jacob Burns Journal: Cochrane Database Syst Rev Date: 2020-12-17